Catalyst Brief

← Calendar

Readoutin 14d

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair — Raloxifene - Usual

Phase 3 primary completion: Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms.

Date
Dec 2026
Type
Readout
Indication
Breast Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

  1. Nov2026